Portfolio company
Aro Biotherapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops tissue-targeted genetic medicines using a proprietary protein technology to treat patients with previously intractable diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Shape Therapeutics
The company develops programmable RNA medicines and delivery systems for patients with genetic disorders and other hard-to-treat diseases.
Aera Therapeutics
This biotechnology company develops delivery platforms for genetic medicines to treat various diseases for biopharmaceutical partners and patients.
Arbor Biotechnologies
This company develops programmable gene-editing tools and genetic medicines to treat patients with liver and central nervous system diseases.
Averna Therapeutics
This biotechnology company develops genomic medicines using RNA-based technology to insert therapeutic genes into safe genomic locations for patients with various diseases.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
Code Bio
This company develops non-viral genetic medicine delivery platforms and therapies for patients with rare and prevalent genetic diseases.
CREATE Medicines
The company develops in vivo CAR therapies using an mRNA platform to treat patients with cancer, autoimmune diseases, and fibrosis.
Akribion Therapeutics
The company develops RNA-guided nuclease technology for programmable cell depletion to treat cancer and autoimmune diseases for healthcare providers and patients.